Trial Information
Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNervous System DiseasesEnrollment763% Female89%% WhiteN/A
Product ClassAnticonvulsantsSponsor Protocol NumberTOPMAT-MIGR-001Data PartnerJohnson & JohnsonCondition StudiedMigraine DisordersMean/Median Age (Years)40.4
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2022-4952 : Topiramate versus oral gepants in the treatment of patients with migraine: a matching adjusted indirect comparison
- 2020-4276 : Psychiatric Symptoms as Adverse Events of Topiramate Therapy: Systematic Review and Meta-Analysis
- 2017-1746 : Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity